Memorial Hospital Research Laboratories

The Britta Weigelt Lab

Share
Back to top

Research

Britta Weigelt, PhD
Britta Weigelt, PhD
Director, Gynecology DMT Research Laboratory

Gynecology DMT Research Laboratory

Our laboratory focuses on the use of high-throughput genomics and functional genomics to identify drivers of rare gynecologic cancer types, and to define the clinical and biological significance of intra-tumor phenotypic and genetic heterogeneity in these tumors. Dr. Weigelt’s laboratory is devising strategies to overcome the challenges posed by intra-tumor genetic heterogeneity, based on state-of-the-art sequencing analyses of circulating cell free (cf)DNA and of single cells. By bringing together traditional pathological techniques with genetic analyses and functional studies, the Weigelt lab seeks to refine the classification of gynecologic cancers and identify novel drivers and potential therapeutic targets of specific tumor types. In addition, Dr. Weigelt is investigating if cfDNA analysis (so-called “liquid biopsies”) can accurately monitor the disease course of women with endometrial or cervical cancer, and if resistance mechanisms to platinum salts or PARP inhibitors in ovarian cancer patients can be identified in cfDNA.

View Lab Overview

The Britta Weigelt Lab

Featured News

Finding
Investigators Lea Moukarzel, Kimberly Dessources, Britta Weigelt, and Sarah Kim in the lab.
Unique Genetic Change Found in Rare Ovarian Tumor Could Spare Patients from Unnecessary Treatment

The research focused on sclerosing stromal tumor, a rare, benign ovarian tumor that is not cancer but can be misdiagnosed as cancer.
In the Lab
Black-and-white microscopic image of cell from human granular cell tumor
A Study of Rare Tumors Uncovers the Presence of Tumor-Suppressing Genes

Studying the genes of granular cell tumors has revealed a previously unknown process through which cells can turn cancerous.
In the Clinic
Man and woman in white lab coats looking at test tubes
Single-Cell Analysis Enables Researchers to Understand the Differences within Tumors

Scientists are decoding the genetic changes that drive individual cancer cells. This may help them develop more-effective targeted therapies.

View All Featured News

Publications

Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. Kim SH, Da Cruz Paula A, Basili T, Dopeso H, Bi R, Pareja F, da Silva EM, Gularte-Mérida R, Sun Z, Fujisawa S, Smith CG, Ferrando L, Martins Sebastião AP, Bykov Y, Li A, Silveira C, Ashley CW, Stylianou A, Selenica P, Samore WR, Jungbluth AA, Zamarin D, Abu-Rustum NR, Helin K, Soslow RA, Reis-Filho JS, Oliva E, Weigelt B. Nat Commun 2020; 11:44. doi: 10.1038/s41467-019-13806-x.

High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer. Ashley CW, Selenica P, Patel J, Wu M, Nincevic J, Lakhman Y, Zhou Q, Shah RH, Berger MF, Da Cruz Paula A, Brown DN, Marra A, Iasonos A, Momeni-Boroujeni A, Alektiar KM, Long Roche K, Zivanovic O, Mueller JJ, Zamarin D, Broach VA, Sonoda Y, Leitao MM, Friedman CF, Jewell E, Reis-Filho JS, Ellenson LH, Aghajanian C, Abu-Rustum NR, Cadoo K, Weigelt B. Clin Cancer Res 2023;29(2):410-421. doi: 10.1158/1078-0432.CCR-22-1134.

View All Publications

People

Britta Weigelt, PhD

Britta Weigelt, PhD

Director, Gynecology DMT Research Laboratory

  • Molecular geneticist Britta Weigelt studies the genomics of gynecologic cancers and the use of circulating cell-free DNA for disease monitoring and the identification of therapy resistance mechanisms.
212-639-2332
Office Phone
View physician profile
Physician profile

Members

Melica N. Brodeur
Melica N. Brodeur

Research Fellow

David Brown

Senior Computational Biologist

Maureen “Moe” Byrne

GYN Oncology Fellow

Jacqueline Feinberg
Jacqueline Feinberg

GYN Oncology Fellow

Olga T. Filippova
Olga T Filippova

GYN Oncology Fellow

Kaitlyn Gill

Research Technician

Sushmita Gordhandas
Sushmita Gordhandas

GYN Oncology Fellow

Hunter Green
Hunter Green

Senior Research Technician

Ryan Kahn
Ryan Kahn

GYN Oncology Fellow

Sarah Kim

Assistant Attending, Gynecology Service, Department of Surgery

Clarissa Lam

GYN Oncology Fellow

Beryl Manning-Geist
Beryl Manning-Geist

GYN Oncology Fellow

Kathryn Miller
Kathryn Miller

GYN Oncology Fellow

Sara Moufarrij

GYN Oncology Fellow

Aaron Praiss
Aaron Praiss

GYN Oncology Fellow

Tiffany Sia
Tiffany Sia

GYN Oncology Fellow

Nancy Varice

Research Project Associate

Michelle Wu
Michelle Wu

Research Project Associate

William A. Zammarrelli III
William A. Zammarrelli III

GYN Oncology Fellow

Lab Alumni
Charles W. Ashley
Charles W. Ashley

GYN Oncology Fellow

Arnaud Da Cruz Paula, PhD
Arnaud Da Cruz Paula

Research Associate

Kimberly Dessources
Kimberly Dessources

GYN Oncology Fellow

Etta Hanlon
Etta Hanlon

Research Technician

Ana Maroldi
Ana Maroldi

Research Technician

Lea Moukarzel, MD
Lea Moukarzel

GYN Oncology Fellow

Evan Smith
Evan Smith

GYN Oncology Fellow

Anthe Stylianou , BSc
Anthe Stylianou

Research Technician

Lab Affiliations

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Britta Weigelt discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures